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Summary
 
Experimental autoimmune encephalomyelitis (EAE) is a widely used animal model for multiple
sclerosis (MS). EAE is typically initiated by CD4
 
1
 
 T helper cell type 1 (Th1) autoreactivity di-
rected against a single priming immunodominant myelin peptide determinant. Recent studies
have shown that clinical progression of EAE involves the accumulation of neo-autoreactivity,
commonly referred to as epitope spreading, directed against peptide determinants not involved
in the priming process. This study directly addresses the relative roles of primary autoreactivity
and secondary epitope spreading in the progression of both EAE and MS. To this end we serially
evaluated the development of several epitope-spreading cascades in SWXJ mice primed with
distinctly different encephalitogenic determinants of myelin proteolipid protein. In a series of
analogous experiments, we examined the development of epitope spreading in patients with
isolated monosymptomatic demyelinating syndrome as their disease progressed to clinically
definite MS. Our results indicate that in both EAE and MS, primary proliferative autoreactivity
associated with onset of clinical disease invariably regresses with time and is often undetectable
during periods of disease progression. In contrast, the emergence of sustained secondary auto-
reactivity to spreading determinants is consistently associated with disease progression in both
EAE and MS. Our results indicate that chronic progression of EAE and MS involves a shifting
of autoreactivity from primary initiating self-determinants to defined cascades of secondary de-
terminants that sustain the self-recognition process during disease progression.
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M
 
ultiple sclerosis (MS)
 
1
 
 and its related animal model,
experimental autoimmune encephalomyelitis (EAE),
are often characterized by a relapsing–remitting disease course
with chronic-progressive disability (1). Typically, EAE is ini-
tiated by CD4
 
1
 
 Th1 autoreactivity directed against a single
immunodominant myelin protein determinant (2, 3). How-
ever, the basis for disease progression is less clear. In the
case of EAE, progression of disease may be attributed either
to sustained autoreactivity directed against an immu-
nodominant priming determinant or to acquired autoreac-
tivity directed against determinants not involved in the ini-
tiation of disease. This acquisition of neo-autoreactivity,
commonly referred to as epitope spreading, presumably
results from endogenous priming with new self-antigens
generated from damaged tissue over the course of disease
(4–7). Similarly, in the case of MS, disease progression may
be due to either a sustained primary autoreactivity or to a
secondary acquisition of neo-autoreactivity as a result of
epitope spreading.
Our study was designed to define the roles of primary
autoreactivity and epitope spreading on the progression of
autoimmune demyelinating disease. To this end, EAE was
induced in SWXJ mice by immunization with a panel of
distinct priming determinants of myelin proteolipid protein
(PLP), and autoreactivity was assessed over time to known
encephalitogenic determinants of PLP, myelin basic protein
(MBP) and myelin oligodendrocyte glycoprotein (MOG).
 
1
 
Abbreviations used in this paper:
 
 CDMS, clinically definite multiple sclero-
sis; CNS, central nervous system; EAE, experimental autoimmune en-
cephalomyelitis; IMDS, isolated monosymptomatic demyelinating syn-
drome; MBP, myelin basic protein; MOG, myelin oligodendrocyte
glycoprotein; MRI, magnetic resonance imaging; MS, multiple sclerosis;
PLP, myelin proteolipid protein; SI, stimulation index. 
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In complementary experiments, autoreactivity to an over-
lapping PLP peptide series was evaluated over a 3-yr period
in patients with isolated monosymptomatic demyelinating
syndrome (IMDS), a group of related neurologic disorders
with variable rates of progression to clinically definite MS
(CDMS; 8–10).
Our results indicate that during progression of EAE, prolif-
erative responses to priming determinants invariably decline
with time and frequently disappear in both the periphery
and in the central nervous system (CNS). The regression of
primary autoreactivity is succeeded by a sequential accumula-
tion of neo-autoreactivity to defined spreading determinants.
Similarly, autoreactivity associated with onset of neurologic
symptoms in IMDS patients consistently wanes with time
and becomes undetectable as disease progresses to CDMS.
The spontaneous waning and frequent disappearance of self-
recognition involved in the initiation of autoimmunity indi-
cates that the natural history of autoimmune disease involves a
shifting of responses from primary initiating determinants to
defined cascades of secondary determinants that sustain the
self-recognition process during disease progression.
 
Materials and Methods
 
Mice.
 
Female SWXJ (H-2
 
q,s
 
) mice were bred at the Biologi-
cal Resources Facility of the Lerner Research Institute by mating
SWR/J (H-2
 
q
 
) females with SJL/J (H-2
 
s
 
) males purchased from
The Jackson Laboratory. Mice were immunized at 7–12 wk of
age. All protocols for animal research met with prior approval of
the Institutional Animal Care and Use Committee (IACUC) of the
Cleveland Clinic Foundation in compliance with the Public Health
Service policy on humane care and use of laboratory animals.
 
Bulk Peptide Synthesis.
 
The PLP peptides 104–117 KTTIC-
GKGLSATVT, 139–151 HSLGKWLGHPDKF (serine for cysteine
at residue 140), and 178–191 NTWTTCQSIAFPSK, as well as
MBP 87–99 VHFFKNIVTPRTP and MOG 92–106 DEGGYTC-
FFRDHSYQ, were either purchased commercially (Bio-Synthe-
sis) or synthesized at the Protein Core Facility of the Lerner
Research Institute with standard solid phase methodology using
amino acids with 9-fluorenylmethoxycarbonyl (FMOC) side
chain protection. Peptides were purified 
 
.
 
90% by reverse phase
HPLC using a 22 
 
3 
 
250 mm C-18 column (Vydac Separations
Group). The identity of each purified peptide was confirmed by
mass spectrometry.
 
Epitope-Mapping PLP Peptide Series.
 
A PLP pin peptide series
representing a walk-through of the entire 276-amino acid pri-
mary sequence of mouse PLP (11, 12) was purchased from Chi-
ron Mimotopes. A total of 265 overlapping 12-mers were syn-
thesized on high-density polyethylene rod tips assembled into
holders designed in 96-well microtiter plate format (13). Each
successive peptide differed from the previous 12-mer by sequen-
tial NH
 
2
 
-terminal deletion and COOH-terminal addition of PLP
amino acids. Upon arrival, 1 mg of each PLP pin peptide was dis-
solved in 500 
 
m
 
l of a solution of 40% acetonitrile (Aldrich Chem-
ical) in 10 mM Hepes buffer (GIBCO BRL). Working aqueous
concentrations of pin peptides were prepared at 150 
 
m
 
g/ml in
PBS, pH 7.2, and 20 
 
m
 
l of each working solution was distributed
sequentially into individual wells of 96-well flat-bottomed micro-
titer Falcon plates (Becton Dickinson). The plates were stored at
 
2
 
20
 
8
 
C until ready for use.
 
Induction of EAE.
 
EAE was induced as previously described
 
(14). SWXJ mice were immunized by subcutaneous injection in
the abdominal flanks on day 0 with 100 nmol of PLP peptides
p139–151 (154 
 
m
 
g), p178–191 (158 
 
m
 
g), or p104–117 (138 
 
m
 
g),
and 400 
 
m
 
g 
 
Mycobacteria tuberculosis
 
 H37RA (Difco Labs.) in 200
 
m
 
l of an emulsion of equal volumes of water and IFA (Difco
Labs.). On days 0 and 3 each mouse also received intravenously
6 
 
3 
 
10
 
9
 
 
 
Bordetella pertussis
 
 bacilli (Michigan Department of Public
Health, Lansing, MI). In the study presented here, all mice devel-
oped clinical EAE within 24 d of immunization.
 
Clinical Evaluation of EAE.
 
All mice were weighed and ex-
amined daily for neurologic signs as previously described (14) ac-
cording to the following criteria: 0, no disease; l, decreased tail
tone or slightly clumsy gait; 2, tail atony and/or moderately
clumsy gait and/or poor righting ability; 3, limb weakness; 4,
limb paralysis; 5, moribund state. The presence of relapse was de-
termined when mice showed an increase in observed neurologic
disability of at least one clinical score unit. The increased neuro-
logic deficit was typically accompanied by an abrupt and substan-
tial (
 
.
 
7%) weight loss.
 
Histologic and Immunocytochemical Evaluation of EAE.
 
Brains
and spinal cords were fixed in 10% phosphate-buffered formalin,
and paraffin-embedded tissue sections were cut (10 mm each) for
immunostaining as previously described (15, 16). Sections were
pretreated with 0.04% OsO
 
4
 
 and 1% H
 
2
 
O
 
2
 
 in 10% Triton (Elec-
tron Microscopy Sciences) and blocked with 5% normal goat
serum (Vector Labs.) and 5% nonfat dehydrated milk for 60 min.
Sections were treated sequentially with PLP monoclonal IgG
 
2a
 
antibody (Harlan) at a 1:200 dilution for 14 h at 4
 
8
 
C, biotinylated
goat anti–mouse IgG
 
2a
 
 (Southern Biotechnology Associates) at a
1:500 dilution for 30 min at 22
 
8
 
C, and avidin-peroxidase com-
plex (Vector Labs.) for 1 h at 1:1,000 dilution. Sections were
then treated with diaminobenzidine and 0.01% H
 
2
 
O
 
2
 
 for 8 min,
0.04% OsO
 
4
 
 for 30 s, and washed in PBS. Images were digitized
using the AlphaImager 2000 System (Alpha Innotech) at 640 
 
3
 
480 pixel resolution. Images were captured at 10
 
3 
 
magnification
with the black level scale set at 0, white level scale at 255, and
gamma level scale at 1.0. All images were normalized by adjusting
background gray matter stain to the same mean intensity value
using Adobe Photoshop (Adobe Systems). The presence of de-
myelination in CNS meninges and parenchyma was determined
visually as well as by digitized image analysis using NIH image soft-
ware (version 1.57; National Institutes of Health, Bethesda, MD).
 
Evaluation of Epitope Spreading during EAE.
 
At wk 2, 4, 8, 12,
and in some cases 16 after immunization of SWXJ mice with a
PLP determinant, splenocytes were tested for proliferative re-
sponses to PLP determinants p104–117 (14, 17), p139–151 (18),
and p178–191 (19), as well as MBP 87–99, an immunodominant
encephalitogenic determinant for both SJL/J (20, 21) and SWR/J
(22) mice, and MOG 92–106, an immunodominant encephalito-
gen for SJL/J mice (23). Mononuclear cells were purified by cen-
trifugation on Lympholyte-M (Accurate Chemical Co.) for 20
min at 2,500 rpm. Cells collected from the interface were washed
three times in HBSS and resuspended in DME (GIBCO BRL)
supplemented with 10% FBS (Hyclone Labs.), 2 mM fresh 
 
l
 
-gluta-
mine, 100 U/ml penicillin, 100 
 
m
 
g/ml streptomycin, 30 mM Hepes
buffer (GIBCO BRL), and 5 
 
3 
 
10
 
2
 
5
 
 M 2-ME. Triplicate test
cultures containing peptide at 20 
 
m
 
g/ml were evaluated at 3 
 
3
 
10
 
5
 
 splenocytes/well in a total volume of 200 
 
m
 
l in 96-well flat-
bottomed microtiter Falcon plates (Becton Dickinson). Triplicate
positive control wells contained mouse CD3 mAb at 5 
 
m
 
g/ml
(PharMingen), or 0.005 tuberculin units/ml of tuberculin puri-
fied protein derivative (PPD; Connaught), or 20 
 
m
 
g/ml 
 
Mycobac-
teria tuberculosis
 
 H37RA (Difco). Dose responses to whole PLP 
1035
 
Tuohy et al.
(0.1–100 
 
m
 
g/ml) were also assessed in each experiment. The PLP
was prepared from a washed total lipid extract of bovine white
matter (24) and was purified and converted to aqueous as previ-
ously described (14). Negative control wells contained no peptide.
Cultures were incubated at 37
 
8
 
C in humidified air containing 5%
CO
 
2
 
. At 4 d, cultures were pulsed with methyl-[
 
3
 
H]thymidine
(l.0 
 
m
 
Ci/well, specific activity 6.7 Ci/mmol; NEN), and the cells
were harvested after 16 h by aspiration onto glass fiber filters.
Levels of incorporated radioactivity were determined by scintilla-
tion spectrometry. Results are expressed as stimulation index (SI)
defined as mean cpm of triplicate experimental cultures with Ag
divided by mean cpm of cultures without Ag.
 
Evaluation of Autoreactivity by CNS-infiltrating Mononuclear Cells.
 
Mononuclear cells were recovered from the CNS at various clin-
ical stages of EAE according to the method of Ford et al. (25). In
brief, SWXJ EAE mice were killed by CO
 
2
 
 inhalation and per-
fused with 20 ml of HBSS to remove hematogenous leukocytes.
Brain tissue was teased and digested with 1 mg/ml of collagenase D
(Boehringer Mannheim) and 50 Kunitz U/ml of DNase (Sigma
Chemical Co.) at 37
 
8
 
C for 60 min. After washing, cells were re-
suspended in Percoll (Amersham Pharmacia Biotech) adjusted
with HBSS to a specific gravity of 1.030 and layered on Percoll/
HBSS at a specific gravity of 1.095. After centrifugation for 30 min
at 1,250 
 
g
 
, cells were removed from the interface, washed, and
counted for total yield. Percentages of T cells (FITC-labeled anti-
CD3 or anti-CD4; PharMingen) and microglia (FITC-labeled
anti-CD11b; PharMingen) were determined by flow cytometry
analysis. Proliferation assays in response to peptides were performed
as described above using 2 
 
3 
 
10
 
5
 
 CNS harvested cells/microtiter
well.
 
Selection and Clinical Evaluation of IMDS Patients.
 
We have
previously reported that monocentric monophasic IMDS patients
with no evidence by history or exam of prior subclinical CNS
disease typically show fully sustained proliferative responses over
a 1-yr period to defined PLP regions (26). The development and
progression of myelin self-recognition was further evaluated over
a total period of 3 yr in three of the original monocentric
monophasic IMDS patients: VS, a 28-yr-old female with inflam-
matory internal capsule syndrome; DL, a 21-yr-old female with
partial transverse myelitis; and JB, a 34-yr-old male with acute
brainstem syndrome. During the course of the study reported
here, both VS and DL showed progression to CDMS at 154 and
60 wk, respectively, after initial onset of their neurologic symp-
toms. Thus far, JB has not shown progression to CDMS. The
three monocentric monophasic IMDS subjects were seen by the
study neurologist (R.P. Kawczak) within 2 wk of the onset of
their neurologic symptoms and were repeatedly examined over
the course of the current study for the evaluation of new symp-
toms. Disease activity in IMDS patients was defined as the occur-
rence of interval clinical or MRI activity as described previously
(26). CDMS was defined as a relapse involving an anatomically
different area of the nervous system compared with onset symp-
toms (27). Magnetic resonance imaging (MRI) was performed as
described previously (26) in a 1.5 Tesla superconducting whole
body imaging system (Siemens Medical System). Image analysis
was performed by two neuroradiologists blinded to the clinical
disposition of the patients. All patients were able to understand
informed consent and comply with the study protocol approved
by the Institutional Review Board of the Cleveland Clinic Foun-
dation.
 
Evaluation of Epitope Spreading during Progression of IMDS to
CDMS.
 
PBMCs from each IMDS subject were serially evaluated
for proliferative responses to the 265 overlapping PLP epitope-
 
mapping peptides as previously described (26). PBMCs were sep-
arated by centrifugation on Ficoll-Paque (Amersham Pharmacia
Biotech), washed three times in HBSS (GIBCO BRL), and
resuspended in serum-free HL-1 media (Hycor) supplemented
with 2 mM fresh 
 
l
 
-glutamine, 100 U/ml penicillin, 100 
 
m
 
g/ml
streptomycin, and 30 mM Hepes buffer (GIBCO BRL). Each
well contained 10
 
5
 
 PBMCs with 15 
 
m
 
g/ml pin peptide in a total
volume of 200 
 
m
 
l. Triplicate positive control wells contained hu-
man CD3 mAb at 10 
 
m
 
g/ml (Ortho Biotech), tetanus toxoid at
1:1,000 dilution (Lederle Laboratories), 0.005 tuberculin U/ml of
tuberculin purified protein derivative (PPD; Connaught), or 20
 
m
 
g/ml 
 
Mycobacteria tuberculosis
 
 H37RA (Difco Labs.) although
negative control wells contained either no peptide or one of 30
irrelevant pin peptides of myohemerythrin, a protein having
minimal sequence homology with myelin proteins (28). Dose re-
sponses to whole bovine PLP (0.1–100 
 
m
 
g/ml) were also assessed
in each experiment. Cultures were incubated at 37
 
8
 
C in humidi-
fied air containing 5% CO
 
2
 
. At 72 h, cultures were pulsed with
methyl-[
 
3
 
H]thymidine (NEN) and harvested and processed as de-
scribed above. Test wells containing 15 
 
m
 
g/ml of a single PLP
peptide were considered positive with an SI 
 
. 
 
2.0 and with a
 
D
 
cpm 
 
. 
 
1,000 and at least three standard deviations above the
mean of nonstimulated control wells. Identification of PLP anti-
genic determinants required that positive proliferative responses
be generated to at least three adjacent overlapping 12-mers.
 
Results
 
Chronic EAE Induced in SWXJ Mice with Three Different
PLP Peptides.
 
SWXJ mice develop acute EAE 
 
z
 
3 wk
after conventional immunization with either of the three
encephalitogenic PLP determinants p104–117, p178–191,
and p139–151 (Fig. 1). Affected mice typically undergo an
incomplete recovery from the initial attack with residual
neuroparalytic signs. Recovery is soon followed by a series
of multiple relapse/remission cycles with each neuropara-
lytic episode leaving the mice progressively more impaired.
By 8–12 wk after immunization, the incremental accumu-
lation of neurologic deficit makes it increasingly more diffi-
cult to observe relapses. This chronic-progressive stage of
EAE is characterized by sustained limb paresis or paralysis
and marked CNS demyelination particularly pronounced
in the spinal cord (Fig. 2).
 
Regression of Primary Autoreactivity during Progression of EAE.
 
To evaluate the changes occurring in self-recognition after
immunization with different encephalitogenic peptides, three
groups of SWXJ mice were immunized with each of the PLP
determinants (p104–117, p178–191, and p139–151), and
splenocytes were tested at various times thereafter for pro-
liferative responses to the three PLP determinants as well
as to the defined encephalitogens MBP 87–99 (20–22) and
MOG 92–106 (23). Three to five independent experiments
were performed for each time point. We found that the ki-
netics of the response to the PLP priming determinants
p104–117 (Fig. 3 a) and p178–191 (Fig. 3 b) were similar,
with peak responses occurring at 2–4 wk, a decline in re-
sponses by 8 wk, and a virtual absence of detectable pro-
liferative responses to the priming immunogens by 12 wk
after immunization. Although the profile of reactivity to the 
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p139–151 priming determinant also showed a rise, peak, and
decline, the kinetics of the p139–151 response were nota-
bly distinct from those of the other PLP determinants, in
that proliferation took longer to peak (8 wk versus 2–4 wk)
and decline (12–16 wk versus 4–8 wk) and reached the
level of control responses in only two out of five mice (Fig.
3 c). Nevertheless, by 12–16 wk after immunization, pro-
liferative responses to three distinct PLP priming determi-
nants invariably declined and were often undetectable despite
the concurrent development of chronic-progressive disease
(Fig. 1).
 
Regression of Primary Autoreactivity Occurs in both Spleno-
cytes and CNS-infiltrating Mononuclear Cells.
 
Since it was
possible that the observed regression of splenocyte respon-
siveness to priming determinants may simply reflect a selec-
tive sequestration of autoreactive T cells from the periphery
into the CNS, we simultaneously compared splenic and CNS
autoreactivities during the course of disease. At distinct clini-
cal stages of EAE, mononuclear cells were isolated from the
brain and tested along with splenocytes for proliferative re-
sponses to priming determinants. In SWXJ mice immu-
nized with both PLP 104–117 (Fig. 4 a) and PLP 178–191
 
(Fig. 4 b), concurrent declines in responses to priming de-
terminants were evident in both splenocytes and CNS-infil-
trating cells during the course of disease. By the second
relapse, complete regression of primary autoreactivity was
clearly evident in both splenocytes and CNS-infiltrating
cells despite the presence of similar numbers of infiltrating
cells compared with onset and first relapse (Fig. 4 c). These
data indicate that regression of primary autoreactivity occurs
simultaneously in both the periphery and CNS.
 
Emergence of Epitope Spreading Cascades during Progression of
EAE.
 
During the regression of primary autoreactivity in
EAE, responses invariably emerged to self-determinants not
involved in the initial priming process. By 4 wk after im-
munization with PLP 104–117 (Fig. 5 a), proliferative re-
sponses to PLP 139–151 (SI
 
 5 
 
2.5) and MBP 87–99 (SI
 
 5
 
2.3) became apparent, peaked by 8 wk (SI
 
 5 
 
3.9 and 3.5,
respectively), and remained markedly elevated at 12 wk when
acquired responses to PLP 178–191 (SI
 
 5 
 
3.6) first became
evident and responses to the p104–117 priming determi-
nant declined toward baseline (SI
 
 5 
 
1.6). In contrast to the
plasticity observed in self-recognition, responses to the prim-
ing adjuvant 
 
Mycobacteria tuberculosis
 
 H37RA showed little
fluctuation throughout the testing period (SI
 
 5 
 
6.13 
 
6 
 
0.24
SEM). Thus, a cascading emergence of neo-autoreactivity
accompanied the regression of primary autoreactivity dur-
ing the development of chronic-progressive disease induced
by immunization with PLP 104–117.
Epitope spreading also accompanied disease progression
in SWXJ mice immunized with PLP 178–191 as indicated
by the appearance of proliferative responses to PLP 139–151
(SI
 
 5 
 
3.2) and MBP 87–99 (SI
 
 5 
 
2.2) 4 wk after priming
with the PLP 178–191 immunogen (Fig. 5 b). Moreover,
the observed neo-autoreactivity remained elevated at 12 wk
Figure 2. CNS demyelination induced by immunization of SWXJ
mice with PLP determinants. Spinal cord sections from EAE mice were
immunostained for detection of PLP. Arrows indicate demyelinated tissue
appearing as unstained areas in digitized images of dorsal columns.
Marked demyelination of the spinal cord was evident during the acute
phase of EAE onset induced within three wk after immunization with (a)
PLP 104–117, (b) PLP 178–191, and (c) PLP 139–151. Demyelination
was also evident in mouse spinal cords during the chronic phase of EAE
12 wk after immunization with (d) PLP 104–117, (e) PLP 178–191, and
(f) PLP 139–151. Sections were taken from mice with either severe pare-
sis or paralysis. Original magnification: 11.73. Bar, 50 mm.
Figure 1. Chronic EAE induced in SWXJ mice with three different PLP
peptides. Immunization of SWXJ mice with either of the three PLP deter-
minants (p104–117, p178–191, and p139–151) induced an acute form of
EAE that eventually progressed to chronicity. Error bars show 6 SEM.1037 Tuohy et al.
(SI 5 3.3 and 3.2, respectively), when proliferative responses
to the priming PLP 178–191 determinant were virtually un-
detectable (SI 5 1.4). Responses to H37RA were similar at
all times tested (SI 5 4.4 6 0.21 SEM).
As described in our previous report (6), a cascading epitope
spreading pattern occurred after immunization of SWXJ mice
with PLP 139–151. A readily detectable response to MBP
87–99 occurred at 8 wk (SI 5 2.6) and remained elevated at
12 wk (SI 5 2.9) when additional neo-autoreactivity to PLP
178–191 (SI 5 3.6) became clearly evident (Fig. 5 c). Re-
sponses to H37RA showed little fluctuation throughout the
testing period (SI 5 4.25 6 0.13 SEM).
Regression of Primary Autoreactivity during Progression of IMDS
to CDMS. To determine whether the concurrent processes
of regressing primary autoreactivity and emerging epitope
spreading occurs during progression of MS, a related series
of experiments was performed using monocentric mono-
phasic IMDS patients who showed no evidence of prior
subclinical disease activity as determined by T2-weighted
MRI. Such patients often progress to CDMS (8–10) and
have been shown in our previous report to develop sus-
tained autoreactivity to defined PLP peptides (26). In serial
evaluation of PBMC-proliferative responses to an overlap-
ping PLP peptide series, three IMDS patients (VS, DL, and
JB) showed sustained autoreactivity to PLP determinants
(p210–244, p116–150, and p117–152, respectively) coincid-
ing with or appearing soon after the diagnosis of IMDS (Fig.
6, a, b, and c, respectively). Serial testing over a 3-yr period
showed that in each case the established autoimmune re-
sponses associated with the early onset stage of the disease
process invariably declined with time and eventually be-
came undetectable.
Emergence of Epitope Spreading during Progression of IMDS
to CDMS. The two IMDS patients, VS and DL, showed
progression to CDMS, and their disease progression was
accompanied by the emergence of PLP neo-autoreactivity
(Fig. 7). At 154 wk after initial onset of neurologic symptoms,
VS was diagnosed with CDMS after developing a cervical
myelitis with a new enhancing MRI lesion of the cervical
spinal cord that corresponded to new symptoms. The pro-
gression to CDMS was associated with the acquisition of
newly acquired secondary responses directed against PLP
Figure 3. Regression of primary autoreactivity
during progression of EAE. By 12 wk after immu-
nization, splenocyte proliferative responses to all
priming determinants invariably declined from
peak levels reached between 2 and 8 wk and were
not evident in most animals immunized with either
(a) PLP 104–117 or (b) PLP 178–191. (c) As shown
in the graph, PLP 139–151–immunized mice
showed a delayed pattern of declining responsive-
ness to the priming determinant. By 16 wk after
immunization responses to PLP 139–151 were de-
tectable but at levels substantially lower than those
observed at 2–12 wk. Each experimental time point
represents the mean response of 5–6 mice. Error
bars show 6 SEM.
Figure 4. Regression of primary autoreactivity occurs in both spleno-
cytes and CNS-infiltrating mononuclear cells. In SWXJ mice immunized
with both (a) PLP 104–117 and (b) PLP 178–191, concurrent declines in
responsiveness to priming determinants were evident in both splenocytes
and CNS-infiltrating cells during the course of disease. (c) As depicted in
the graph, the numbers of mononuclear cells recovered from the CNS
during onset and relapse were consistently greater than numbers recov-
ered during stages of remission. This observation was evident even during
late relapse and remission stages when complete regression of primary au-
toreactivity was clearly evident in CNS-infiltrating cells. Typically, CD31
T cells comprised 70%, 15%, and 40% of total recovered mononuclear cells
in acute EAE, remissions, and relapses, respectively. The remaining cells
were predominantly CD11b1 microglia. Error bars show 6 SEM.1038 Spontaneous Regression of Autoreactivity in EAE and MS
50–69 (SI 5 4.7) at 154 wk and both PLP 167–185 (SI 5
2.4) and PLP 258–271 (SI 5 3.4) at 170 wk (Fig. 7 a). At
154 wk and after, there were no detectable proliferative re-
sponses to the primary PLP 210–244 region associated with
the early disease stage.
Patient DL showed progression from IMDS to CDMS
60 wk after initial onset of symptoms after developing symp-
toms consistent with a brainstem syndrome. Disease progres-
sion was associated with the development of a secondary
spreading response to PLP 49–62 (SI 5 2.4) at 54 wk equal
in magnitude to the autoreactivity directed against PLP 116–
150 (SI 5 2.4), a determinant that once generated a vigor-
ous sustained autoreactivity during the onset stage of IMDS
(Fig. 7 b). At 82 wk, the response to the spreading determi-
nant PLP 167–182 (SI 5 2.7) was greater than that elicited
by PLP 116–150 (SI 5 2.3) and was even greater by 162
wk (SI 5 3.2) when the response to the initial autoreactive
PLP 116–150 was undetectable (SI 5 1.1).
Thus far, patient JB has not progressed to CDMS. How-
ever, at 148 wk after initial onset of symptoms, JB developed
the first indications of neo-autoreactivity with responses di-
rected against PLP 261–274 (SI 5 2.4) unaccompanied by
detectable responses to PLP 117–152 associated with the
early onset stage of IMDS (SI 5 1.1; Fig. 7 c). Throughout
the experimental period, fluctuations occurring in positive
control responses of VS, DL, and JB showed no correlation
with changes observed in primary and spreading autoreac-
tivities (data not shown).
Discussion
Our results indicate that progression of both EAE and
MS is consistently accompanied by the spontaneous de-
crease and frequent disappearance of the established pri-
mary autoreactivity and the concurrent emergence of the
epitope-spreading cascade. Our findings are consistent with
the view that progression of autoimmune disease involves
the sequential appearance and regression of responses to a
cascading series of self-determinants so that at any given
time the response to one of several distinct determinants
may appear to be predominant. Indeed, based on the prolif-
Figure 5. Emergence of epitope spreading cascades during progression
of EAE. Progression of EAE coincided with regression of primary auto-
reactivity and with the concurrent emergence of epitope spreading cas-
cades. (a) SWXJ mice primed with PLP 104–117 showed neo-autoreac-
tivity to MBP 87–99 and PLP 139–151 followed by responsiveness to
PLP 178–191. (b) Mice primed with PLP 178–191 showed epitope
spreading to PLP 139–151 and MBP 87–99. (c) Mice primed with PLP
139–151 showed sequential recognition of MBP 87–99 and PLP 178–
191. In all cases, variations in positive control responses to H37RA
showed no correlation with the changes observed in primary and spread-
ing autoreactivities. Error bars show 6 SEM.
Figure 6. Regression of primary autoreactivity
during progression of IMDS to CDMS. Three
monocentric monophasic IMDS patients (a) VS, (b)
DL, and (c) JB showed sustained autoreactivity to
PLP peptides coinciding with or soon after initial
onset of neurologic symptoms. In each case, the es-
tablished primary autoreactivity uniformly de-
clined with time and eventually disappeared. Error
bars show 6 SEM.1039 Tuohy et al.
erative responses at 12–16 wk after immunization, it would
be most difficult if not impossible to identify the determi-
nant used as the priming immunogen for EAE induction in
every case examined (Fig. 5). Thus, the concept of immu-
nodominance as it pertains to the natural development of
self-recognition during autoimmune disease may best be
understood when considered in the temporal context of an
“epitope du jour” perspective.
Our study directly challenges the widely held view that
EAE and most notably MS are initiated and maintained by au-
toreactivity directed against a single predominant myelin pro-
tein or determinant. Several studies have claimed that auto-
reactivity in MS is directed in a predominant manner against
specific myelin proteins and their defined immunodominant
determinants. Predominant MHC class II–restricted responses
have been described for peptides in the MBP 80–105 re-
gion (29–32) as well as for PLP peptides p40–60 (33), p89–
106 (34), p30–49, and p180–199 (35). Recent studies also
claim a predominance of autoreactivity to MOG over other
myelin proteins in MS patients (36). However, conclusions
from these studies are based invariably on data taken at one
time point from patients with long-standing disease. Thus,
it is not surprising that a one-dimensional view of self-recog-
nition would prevail from such a static perspective. Serial
evaluation of self-recognition over a period of time sufficient
to observe progression of clinical disease clearly reveals shifts
from one predominant autoreactive pattern to another.
It is likely that the level of self-recognition remodeling
observed in the study reported here during progression of
EAE and MS effectively under-represents the dynamic
level of the changes that actually occur. This view is pro-
posed in light of the fact that PLP served as the sole autoan-
tigen evaluated in this study and that proliferation was the
only assay used for measuring autoreactivity. The actual
level of self-recognition plasticity may best be estimated by
serial assessment of the autoreactive changes to overlapping
peptides of several myelin proteins implicated in MS auto-
reactivity, such as PLP, MBP, and MOG, as well as by the
incorporation of more sensitive assays such as the ELISPOT
capable of providing a 10–200-fold increased sensitivity
over conventional methods for detecting immunoreactivity
(37, 38) and the use of soluble peptide–MHC tetramers that
enable frequency analysis of antigen-specific T cells by flow
cytometry (39).
It seems reasonable to speculate that shifts from one epi-
tope response pattern to another may also be accompanied by
a broadening in usage of MHC class II molecules restricting
the autoreactivity. Moreover, it may be possible to sustain re-
sponses to a given determinant by expanding the autoreactive
repertoire with clones that utilize restriction elements not
involved in the primary response. A recent report from our
laboratory showed that during progression from IMDS to
CDMS, a patient homozygous for DRB1*04 responded in a
DPB1*0301-restricted manner to PLP 43–64 (40), a peptide
region shown in other studies to be DRB1*04 restricted (33).
Thus, autoimmune spreading may involve diversification of
restriction elements in addition to broadening of epitopes rec-
ognized. From this perspective, both epitope spreading and
“MHC spreading” may participate together to sustain autore-
activity and thereby facilitate chronic progression of autoim-
mune disease.
Although shifts from primary to secondary autoreactive
profiles were observed in both MS and EAE, each step in the
process was markedly prolonged in MS. Typically, primary
autoreactivity was detectable for over 1 yr in MS compared
with 12 wk for PLP 104–117 and PLP 178–191 in murine
EAE. Highly developed secondary patterns of autoreactiv-
ity occurred within weeks or months of onset of clinical
symptoms in murine EAE but often required years to develop
during progression of IMDS to MS. However, it should be
noted that the contrasting self-recognition kinetic profiles of
EAE versus MS were accompanied by corresponding differ-
ences in the development and progression of clinical symp-
toms, i.e., progression of murine EAE occurs within a few
months, whereas progression of IMDS to CDMS often de-
velops over many months or years. Thus, it appears that the
shifting autoreactivity observed in SWXJ EAE mice repre-
Figure 7. Emergence of epitope spreading during progression of IMDS
to CDMS. Two IMDS patients (VS and DL) eventually showed progres-
sion to CDMS accompanied by the emergence of neo-autoreactivity. (a)
VS showed secondary responses to PLP 50–69 at 154 and 170 wk and to
both PLP 167–185 and PLP 258–272 at 170 wk. Epitope spreading at on-
set of CDMS at 154 wk was unaccompanied by detectable proliferative
responses to the PLP 210–244 region implicated in earlier stages of the
disease process. (b) In the case of DL, disease progression at 60 wk in-
volved a clear sustained response to the newly acquired PLP 167–182 at
82 and 162 wk in the absence of responsiveness to the PLP 116–150 re-
gion associated with initial onset of symptoms. (c) Thus far, JB has not
shown any progression to CDMS. However, at 148 wk JB showed the
first signs of neo-autoreactivity with responses to PLP 261–274 unaccom-
panied by detectable responses to the primary PLP 117–152 associated
with onset of IMDS. Error bars show 6 SEM.1040 Spontaneous Regression of Autoreactivity in EAE and MS
sents an accelerated version of the same underlying pro-
cesses responsible for the development of self-recognition
in MS.
The shifting patterns of self-recognition shown in this
study functionally reveals the fundamental underlying in-
stability of the autoreactive T cell repertoire in MS. This
view is supported by other studies showing changes in T
cell repertoire restriction in IMDS patients who progress to
CDMS (41). The inherent plasticity of the autoreactive
repertoire has implications with regard to therapeutic appli-
cations, perhaps most notably evident in clonotypic thera-
pies targeting specific TCR genes. Such T cell vaccination
approaches result in the emergence of new autoreactive rep-
ertoires using TCR genes distinct from those used by the
original responding T cells (42). Thus, the inherent capac-
ity of the immune system to provide a continual source of
neo-autoreactivity may serve ultimately as a basis for under-
mining the effectiveness of TCR-based therapies that fail to
target the secondary spreading repertoires.
Recently, it has been suggested that it may be possible to
harness epitope spreading in such a manner as to facilitate
the spread of immune suppression during autoimmune dis-
ease (43). Prior reports have shown that chronic progression
of EAE can be inhibited by inducing intramolecular (5) or
intermolecular (6) tolerance to determinants of the epitope
spreading cascade. Recent studies in our laboratory indicate
that adoptive Th2 immunotherapy targeting spreading deter-
minants results in a marked long-term inhibition of EAE
progression even when transfer occurs before the develop-
ment of endogenous self-priming (44). Thus, stacking the
T cell repertoire to favor an active Th2 response to spread-
ing determinants may subvert the neo-autoreactive process
and produce a long-lasting therapeutic outcome. In this re-
gard, peptide-based therapies such as those incorporating
the HFFK amino acid motif of the putative human immu-
nodominant MBP determinant (45, 46) or those involving
altered peptide ligand strategies (47, 48) may prove to be
most effective if the repertoire capable of responding thera-
peutically to the selected peptide has undergone minimal
spontaneous regression.
It is evident from this study that progression of both EAE
and MS may occur in the absence of primary initiating
autoreactivity. However, thus far the basis for regression of
primary autoreactivity is unclear. Our data indicate that the
disappearance of primary self-recognition is not due to se-
questration of autoreactive T cells in the CNS thereby cre-
ating an apparent loss of systemic autoreactivity. Therefore,
more intricate explanations are needed to account for the
spontaneous disappearance of self-recognition. Chronic self-
stimulation may result in T cell exhaustion and peripheral
clonal deletion (42), perhaps through apoptosis (49, 50).
Alternatively, autoreactive T cells may be present but unre-
active as a result of T cell anergy (51–54) or suppression (55,
56). Studies designed to determine the underlying mecha-
nism(s) responsible for the regression of primary autoreac-
tivity and the emergence of epitope spreading are currently
in progress.
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